179 related articles for article (PubMed ID: 16380629)
41. A transient neonatal myasthenic syndrome with anti-musk antibodies.
Niks EH; Verrips A; Semmekrot BA; Prick MJ; Vincent A; van Tol MJ; Jol-van der Zijde CM; Verschuuren JJ
Neurology; 2008 Apr; 70(14):1215-6. PubMed ID: 18378885
[No Abstract] [Full Text] [Related]
42. Anti-MuSK antibodies: correlation with myasthenia gravis severity.
Bartoccioni E; Scuderi F; Minicuci GM; Marino M; Ciaraffa F; Evoli A
Neurology; 2006 Aug; 67(3):505-7. PubMed ID: 16894117
[TBL] [Abstract][Full Text] [Related]
43. MuSK antibody-positive, seronegative myasthenia gravis in Korea.
Lee JY; Sung JJ; Cho JY; Oh DH; Kim HJ; Park JH; Lee KW; Choi YC; Vincent A
J Clin Neurosci; 2006 Apr; 13(3):353-5. PubMed ID: 16546389
[TBL] [Abstract][Full Text] [Related]
44. Quantitative EMG of facial muscles in myasthenia patients with MuSK antibodies.
Farrugia ME; Kennett RP; Hilton-Jones D; Newsom-Davis J; Vincent A
Clin Neurophysiol; 2007 Feb; 118(2):269-77. PubMed ID: 17157556
[TBL] [Abstract][Full Text] [Related]
45. MuSK-antibody positive myasthenia gravis: questions from the clinic.
Sanders DB; Juel VC
J Neuroimmunol; 2008 Sep; 201-202():85-9. PubMed ID: 18684517
[TBL] [Abstract][Full Text] [Related]
46. Dysphagia and respiratory failure in an HIV patient: MuSK myasthenia gravis.
Wirtz PW
Acta Neurol Belg; 2020 Dec; 120(6):1483-1484. PubMed ID: 32851549
[No Abstract] [Full Text] [Related]
47. Clinical phenotype of muscle-specific tyrosine kinase-antibody-positive myasthenia gravis.
Wolfe GI; Oh SJ
Ann N Y Acad Sci; 2008; 1132():71-5. PubMed ID: 18567855
[TBL] [Abstract][Full Text] [Related]
48. The search for new antigenic targets in myasthenia gravis.
Cossins J; Belaya K; Zoltowska K; Koneczny I; Maxwell S; Jacobson L; Leite MI; Waters P; Vincent A; Beeson D
Ann N Y Acad Sci; 2012 Dec; 1275():123-8. PubMed ID: 23278587
[TBL] [Abstract][Full Text] [Related]
49. An ocular form of myasthenia gravis with a high titer of anti-MuSK antibodies during a long-term follow-up.
Hosaka A; Takuma H; Ohta K; Tamaoka A
Intern Med; 2012; 51(21):3077-9. PubMed ID: 23124154
[TBL] [Abstract][Full Text] [Related]
50. Two sisters with anti-MuSK-positive myasthenia gravis.
Kurt E; Bekircan-Kurt CE; Konuşkan B; Erkent İ; Tan E; Anlar B
Clin Neurol Neurosurg; 2019 Jul; 182():17-18. PubMed ID: 31054424
[No Abstract] [Full Text] [Related]
51. Strong association of MuSK antibody-positive myasthenia gravis and HLA-DR14-DQ5.
Niks EH; Kuks JB; Roep BO; Haasnoot GW; Verduijn W; Ballieux BE; De Baets MH; Vincent A; Verschuuren JJ
Neurology; 2006 Jun; 66(11):1772-4. PubMed ID: 16769963
[TBL] [Abstract][Full Text] [Related]
52. Cholinergic neuromuscular hyperactivity in patients with myasthenia gravis seropositive for MuSK antibody.
Punga AR; Flink R; Askmark H; Stålberg EV
Muscle Nerve; 2006 Jul; 34(1):111-5. PubMed ID: 16453324
[TBL] [Abstract][Full Text] [Related]
53. Expression of extracellular domains of muscle specific kinase (MuSK) and use as immunoadsorbents for the development of an antigen-specific therapy.
Skriapa L; Zisimopoulou P; Trakas N; Grapsa E; Tzartos SJ
J Neuroimmunol; 2014 Nov; 276(1-2):150-8. PubMed ID: 25262156
[TBL] [Abstract][Full Text] [Related]
54. Neurophysiological and mitochondrial abnormalities in MuSK antibody seropositive myasthenia gravis compared to other immunological subtypes.
Rostedt Punga A; Ahlqvist K; Bartoccioni E; Scuderi F; Marino M; Suomalainen A; Kalimo H; Stålberg EV
Clin Neurophysiol; 2006 Jul; 117(7):1434-43. PubMed ID: 16737845
[TBL] [Abstract][Full Text] [Related]
55. Anti-alkaline phosphatase antibody positive myasthenia gravis.
Konishi T; Ohta K; Shigemoto K; Ohta M
J Neurol Sci; 2007 Dec; 263(1-2):89-93. PubMed ID: 17628604
[TBL] [Abstract][Full Text] [Related]
56. Vocal cord paralysis as a manifestation of myasthenia gravis with anti-MuSK antibodies.
Jiménez Caballero PE; Fermin Marrero JA; Trigo Bragado I; Casado Naranjo I
Neurologia; 2014 May; 29(4):253-4. PubMed ID: 23040717
[No Abstract] [Full Text] [Related]
57. Repetitive nerve stimulation of facial muscles in MuSK antibody-positive myasthenia gravis.
Oh SJ; Hatanaka Y; Hemmi S; Young AM; Scheufele ML; Nations SP; Lu L; Claussen GC; Wolfe GI
Muscle Nerve; 2006 Apr; 33(4):500-4. PubMed ID: 16392120
[TBL] [Abstract][Full Text] [Related]
58. A potential role for B-cell activating factor in the pathogenesis of autoimmune myasthenia gravis.
Ragheb S; Lisak R; Lewis R; Van Stavern G; Gonzales F; Simon K
Arch Neurol; 2008 Oct; 65(10):1358-62. PubMed ID: 18852352
[TBL] [Abstract][Full Text] [Related]
59. Two cases of thymoma-associated myasthenia gravis without antibodies to the acetylcholine receptor.
Maggi L; Andreetta F; Antozzi C; Confalonieri P; Cornelio F; Scaioli V; Mantegazza R
Neuromuscul Disord; 2008 Aug; 18(8):678-80. PubMed ID: 18657424
[TBL] [Abstract][Full Text] [Related]
60. Long-term benefit of rituximab in MuSK autoantibody myasthenia gravis patients.
Keung B; Robeson KR; DiCapua DB; Rosen JB; O'Connor KC; Goldstein JM; Nowak RJ
J Neurol Neurosurg Psychiatry; 2013 Dec; 84(12):1407-9. PubMed ID: 23761915
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
